Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 30Thoracic 15Other solid neoplasm 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Other neoplasm 1Genitourinary 1Endocrine 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Ramucirumab × Head & Neck × Clear all
NCT03650764 2026-05-15

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

Phase 1/2 Completed
43 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05980000 2026-03-31

Rambro2

Washington University School of Medicine

Phase 2 Active not recruiting
37 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡